Crohn’s disease (CD), one of the main forms of inflammatory bowel disease, is characterized by patchy transmural inflammation that can involve any part of the digestive tract, from mouth to anus (Baumgart and Sandborn, 2012). Treatments for CD include the use of medication, alterations in diet and nutrition, and sometimes surgical procedures to repair or remove affected portions of digestive tract (Gajendran et al., 2018; Shi and Ng, 2018), however, no cure has been developed. In recent years, the global incidence of CD has been continuously increasing (Torres et al., 2017). Although a large number of studies have been conducted, the etiology of CD is still not clear. Many studies have revealed that there is a close relationship between the gut microbiota and CD. Dysbacteriosis is a typical symptom of CD patients, which includes reduced diversity, altered structural composition, and dysfunction of the gut microbiota (Gevers et al., 2014; De Cruz et al., 2015; Teh et al., 2021). The presence of gut microbes has been shown to be necessary for the occurrence of CD-related pathological changes in genetically susceptible mice (Kobayashi et al., 2014). Clinical observations from patients have demonstrated that CD lesions occur more frequently within the terminal ileum, which is an area with increased bacterial contact (Baumgart and Sandborn, 2012). Treatments, such as antibiotics and fecal microbiota transplantation, have been shown to alleviate CD, which also indicates the correlation between the intestinal microbiota and the inflammatory response (Selby et al., 2007). Genome-wide association studies have found more than 100 susceptibility loci in the genomes of CD patients (Sazonovs et al, 2022), and these susceptibility sites are mostly involved in microbial recognition and defense-related pathways (Hampe et al., 2001; Hampe et al., 2007). A nationwide case-control study showed that acute gastrointestinal infections increase the risk for CD, and speculated that the pathogens causing acute infectious gastroenteritis might play a role in the occurrence and development of CD (Axelrad et al., 2019).

Yersinia enterocolitica is the fourth most common bacterium causing acute infectious gastroenteritis in the European Union (EU) (Spackova et al., 2022). As a zoonotic pathogen which is widely distributed in nature, it is often transmitted to humans through consumption of contaminated food or water (Bottone, 1999). Compared with other bacteria, Y. enterocolitica is more frequently observed in CD lesions (e.g., CD specimens of mesenteric lymph nodes and Peyer’s plaques) (Lamps et al., 2003; Leu et al., 2013; Le Baut et al., 2018). Besides, there are many overlaps between Y. enterocolitica infection and CD in clinical symptoms and pathological manifestations, which often cause misdiagnosis and delays in treatment (Naddei et al., 2017; Cian et al., 2020). However, it is still unclear whether the presence of Y. enterocolitica in CD is a concomitant or accidental phenomenon or a contributing factor in the pathogenesis of CD. Therefore, we comprehensively investigate the relationship between Y. enterocolitica and CD from multiple aspects in this review, including pathological manifestations, diagnosis, treatment, epidemiology, and pathogenesis.

Y. enterocolitica is a member of the phylum Proteobacteria, family Enterobacteriaceae, and genus Yersinia, which was first discovered and named in the mid-20th century (McIver and Pike, 1934; Schleifstein and Coleman, 1939; Hässig et al., 1949; Frederiksen, 1964). Generally, there are 18 classical strains (currently, more strains have been found using whole genome sequencing and gene alignment algorithms), most of which are regarded as environmental, non-virulent human pathogens (Sulakvelidze, 2000). Of the 18 strains, 3 are pathogenic to humans, namely, Yersinia pestis (the causative agent of plague, including the medieval ‘Black Death’), Yersinia pseudotuberculosis, and Y. enterocolitica (Achtman et al., 1999). The latter two can cause gastrointestinal disorders, of which, Y. enterocolitica is more relevant to gastrointestinal infections in humans. Y. enterocolitica can be further divided into a variety of biochemical and serological heterogeneous strains. To date, six biotypes (1A, 1B, 2, 3, 4, and 5) and more than 70 serotypes have been identified. Among them, biotype 1B strains (also named ‘New World’ or American strains due to their initial isolation in the USA) are considered highly virulent and lethal in mice, while biotype 1A strains are considered non-virulent due to the absence of the virulent plasmid pYV. Biotypes 2, 3, 4, and 5 (‘Old World’ or European strains) are low-virulence. The most common strains isolated from symptomatic humans belong to serobiotypes O: 3/4, O: (5 and 27)/(biotypes 2 and 3), O: 8/1B, and O: 9/2 (Lucero-Estrada et al., 2020).

A series of studies on Y. enterocolitica from 1930 to the present have focused on the identification and comparison of strains, the molecular mechanism of effector proteins in virulence and pathogenesis, clinical symptoms, and epidemiology ( Figures 1A–C ). Using scientometric analysis, we found that published studies regarding Y. enterocolitica were mainly from Europe and North America before 1980 ( Figure 2A ). After then, a number of studies were published from Asia, South America, and Africa ( Figure 2B ). In 1981, Kaneko et al. isolated Y. enterocolitica in Hokkaido, Japan, while retrospectively discovering that there had been several outbreaks of Y. enterocolitica community infection have occurred in Japan (Kaneko and Hashimoto, 1981). Sun et al. reported in the Chinese Journal of Zoonoses that 107 residents of Lanzhou City were infected after consuming contaminated beef in 1987, which was the earliest publication of an outbreak of Y. enterocolitica in China (Dianbin Sun and Wei, 1987). At present, the intimate relationship between Y. enterocolitica and CD has been widely recognized (Hugot et al., 2021). The epidemiology, clinical symptoms, pathological manifestations, and molecular mechanisms of this relationship are discussed in detail below.

The epidemiology of Y. enterocolitica and CD seem to have a strong correlation. Compared to control groups, CD patients had a significantly higher prevalence of Y. enterocolitica. As many as 63% of patients with CD were found to have Y. enterocolitica based on the investigation by Kallinowski et al. (1998). As per Lamps et al., the detection rate of pathogenic Y. enterocolitica DNA in the bowel and mesenteric lymph nodes from patients with CD reached 31% (17/54), while all control tissues (40 cases of normal intestinal specimens, 30 cases of acute appendicitis, and 50 cases of active colitis) were negative (Lamps et al., 2003). Ahmad et al. showed that Y. enterocolitica was frequently present in patients with CD (7/69, 10.14%), and was significantly associated with the disease (p = 0.02) (Khan et al., 2021). Both Y. enterocolitica infection and the onset of CD in humans have obvious familial aggregation. One infection mode of Y. enterocolitica is a family-centered, small-scale outbreak (Black and Slome, 1988). Moreover, 12% to 18% of CD patients are reported to have at least one household member who suffers from the disease (Weterman and Pena, 1984). In a study on familial CD in Belgium, Herbert et al. found that CD patients and their relatives consumed more unpasteurized milk and cheese, undercooked beef, and pork than the control population (Van Kruiningen et al., 2005). It is speculated that these food with high chance of Y. enterocolitica contaminations may be a potential trigger of CD.

Global trends in the prevalence of CD and Y. enterocolitica infection are also similar. Historically, the outbreaks and epidemics of Y. enterocolitica infection and CD cases mostly have been reported in the northern hemisphere such as North America and Northern Europe (Bottone, 1977; Molodecky et al., 2012). Currently, there has been a weakened north-south gradient in Y. enterocolitica transmission and CD in recent decades, which may be attributed to the advancement of global modernization. According to data from the European Centre for Disease Prevention and Control (ECDC) and Foodborne Diseases Active Surveillance Network (FoodNet) in the United States, the incidence of Y. enterocolitica in Europe and the United States has decreased over the past decade ( Figure 3 ). Meanwhile, an increasing incidence of Y. enterocolitica has been found in some low-risk areas in the past. Meta-analysis of the global annual incidence of Y. enterocolitica in gastroenteritis cases between January 1, 2000 and December 31, 2019 showed that Africa and the Eastern Mediterranean rank first and second respectively in the global prevalence of Y. enterocolitica (Riahi et al., 2021). Correspondingly, newly industrialized regions from Asia, Africa, and South America are experiencing an increase in CD cases (Giegerich et al., 2018), and New Zealand and Australia are among the top four countries with the highest annual incidence of CD at present (Torres et al., 2017). Notably, bacterial infections such as Yersinia are more likely to be diagnosed and treated than those of a chronic disease such as CD, which may also contribute to global incidence changes. Taken together, these evidences suggest that Y. enterocolitica has a strong epidemiological relationship with CD. However, the mechanism underlying this association is unknown. Furthermore, it is unclear if interactions between Y. enterocolitica and CD-susceptible individuals initiate the onset of disease. Thus, further investigations regarding Y. enterocolitica infection and CD patients are needed.

Infection of Y. enterocolitica disturbs immune balance in the host. The pathogenesis depends on multiple chromosome-encoded and plasmid-encoded virulence determinants ( Table 1 ) ( Figure 4 ). Once entering the digestive tract, Y. enterocolitica first passes through the gastric acid barrier with the help of urease (Righetto et al., 2020). After reaching the distal small intestine, it preferentially adheres to and invades M cells in the follicular-associated epithelium (FAE). The interactions between bacterial adhesins and β1-integrins on the surface of M cells induce Y. enterocolitica internalization by stimulating the remodeling of actin filaments and forming a polymerized actin vacuole (Schulte et al., 2000). Then the vacuole transports from the apical to the basal side of the M cell, where Y. enterocolitica is expelled into the lymphoid follicles of the Peyer’s patches (Autenrieth and Firsching, 1996). With the help of Yad and invasion proteins, Y. enterocolitica adheres to the host immune cells (including macrophages, neutrophils, dendritic cells, and monocytes) surfaces (El Tahir and Skurnik, 2001; Heise and Dersch, 2006). At the same time, the T3SS injection system forms a channel between Y. enterocolitica and the target cell and injects cytotoxic effector Yersinia outer-membrane proteins (Yops) into the cytoplasm of the host cell, enabling the bacteria to evade the host immune system (Cornelis, 2006; Cornelis, 2010). For example, YOPs, such as YopE, YopH, YopT, and YopO, inhibit the phagocytosis of macrophages and leukocytes by disrupting the actin cytoskeleton. YopP inhibits multiple signaling pathways, including TNF-α and IL-8, and exploits lipopolysaccharide signaling to trigger apoptosis in infected macrophages and dendritic cells (Denecker et al., 2002). In addition, the immunomodulatory protein Gal-1 can promote the replication of Y. enterocolitica in PP, and this protein has been shown to play a role in limiting bacterial clearance (Davicino et al., 2017). After the incubation period of 4–7 days, the engulfed bacteria migrate to the mesenteric lymph nodes, where they multiply and cause abscess formation (Hein et al., 2000). Systemic infection occurs with the migration of Y. enterocolitica along with the lymphatic fluid or blood and may cause extraintestinal complications, such as sepsis (Lai et al., 2014), deep organ abscess (Viteri et al., 1981; Demes et al., 2021), and arthritis (Appel et al., 2002). Moreover, YadA-mediated complement evasion may result in persistent pathogen presence (China et al., 1993).

Both Y. enterocolitica infection and CD exhibit immune defects during pathogenesis, with some immune responses shared. A break of the balance between immunosurveillance and immune escape of the intestinal microbiota is crucial in the pathogenesis of CD. For example, both mutations in MUC2, which encodes for intestinal mucus, and the emulsifiers commonly found in Western diets are risk factors for CD, as they both lead to the destruction of the mucus layer and create opportunities for the translocation of intestinal pathogens, such as Y. enterocolitica (Boltin et al., 2013; Chassaing et al., 2015). The susceptibility genes of CD are mostly related to microbial recognition and defense. CARD15, originally named NOD2, is the first identified susceptibility gene of CD. Its encoding protein NOD-like receptors (NLRs) expressed in the cytoplasm of many innate immune cells, respectively, is a main group of pattern recognition receptors (PRRs) responsible for recognizing intestinal microbiota (Al Nabhani et al., 2017). Individuals carrying CARD15 mutations were reported to present with abnormal immune responses to Y. enterocolitica infection and are subsequently diagnosed with CD (Safa et al., 2008). Toll-like receptors (TLR) expressed in the membrane of many innate immune cells, is another main group of PRRs. TLR1^-/- mice with acute Y. enterocolitica infection exhibit CD-like symptoms post-infection, including poor weight gain, dysbiosis, long-term chronic inflammation, and an increased anti-commensal immunity as compared to their wild-type (WT) littermate control mice (Kamdar et al., 2016). The autophagy process, which is also affected by Y. enterocolitica infection, has a vital role in downstream antibacterial mechanisms mediated by the TLR and NLR signaling pathways. Murthy et al. found that Y. enterocolitica could activate caspase 3 after infection, leading to the accelerated degradation of the CD-susceptible autophagy gene ATG16L1 (T316A), which in turn, led to reduced autophagy, impaired pathogen clearance of ileal Y. enterocolitica, and increased secretion of TNF-α and IL-1β (Murthy et al., 2014). The detailed molecular mechanisms involved are the effects of Y. enterocolitica and derived microbial compounds on immune cells. For example, YopE has a Rho GTPase-activating protein domain (GAP), which targets RhoA, Rac1 and Cdc42. By hitting Rho-GTPases, YopE not only attenuates the production of IL-8 (CXCL8), an important chemoattractant and activator for neutrophils, but also affects neutrophil migration, which is largely dependent on Rho-mediated signaling (Viboud et al., 2006; Amulic et al., 2012; Grabowski et al., 2017). YopO has a guanine nucleotide dissociation inhibitor (GDI) domain, which binds to GDP-bound forms of Rac and RhoA, and thus prevents their activation, resulting in the inhibition of stress fiber formation, impairs the phagocytosis of bacteria by macrophage (Barz et al., 2000). YopP inhibits multiple signaling pathways, including the NF-κB and MAPKs pathways, and exploits lipopolysaccharide -related signaling pathway to trigger apoptosis in infected macrophages and DC (Ruckdeschel et al., 2001). YopP makes the down-regulation of cytokines, chemokynes and adhesion molecules (Boland and Cornelis, 1998), and inhibits the recruitment and activation of macrophages and natural killer cells to the site of infection, so helps the bacteria evade the host inflammatory response (Navarro et al., 2005).

Y. enterocolitica infection can evoke a long-term immune response and gut microbiota alteration, then lead to developing of CD in genetically susceptible individuals. As Netea et al. reported, the defects in the recognition pathways of TLR5 and NOD2 led to a defective inflammatory response to Y. enterocolitica and long-term abdominal inflammation (Netea et al., 2010). Denise et al. suggested that constant disruption in the communication between the immune system and tissue systems following clearance of an acute infection denotes a turning point in which both tissue and immune homeostasis were altered via long-term reprogramming (Fonseca et al., 2015). Therefore, we suggested that long-term reprogramming of immune cells after Y. enterocolitica infection, as well as profound and persistent remodeling of MAT and MLN, leads to the development of chronic inflammatory conditions through a phenomenon known as immunological scarring. Of course, this speculation needs to be confirmed by further studies.

It was noted decades ago that there were many similar pathological manifestations and clinical symptoms between CD and Y. enterocolitica infection ( Table 2 ). For instance, the location of lesions in both diseases is most frequently presented in the terminal ileum - areas with increased bacterial contact (Payne et al., 1987). Specifically, the Peyer’s patches and isolated lymphoid follicles in the small intestine, where Y. enterocolitica primarily colonizes (Revell and Miller, 2001), are also sites for typical aphthoid lesions during the early stage of CD (Lockhart-Mummery and Morson, 1960; Fujimura et al., 1996; Krauss et al., 2012). Different from the ulcers caused by local intestinal ischemia, Behcet’s disease and intestinal tuberculosis tend to occur on the mesenteric side of the intestinal lumen (Sunada et al., 2009). The main clinical symptoms in humans infected with Y. enterocolitica include abdominal pain, diarrhea, and vomiting. Endoscopic observation shows ileal edema, thickening of the intestinal mucosal, epithelioid granuloma, lymphoid tissue swelling, and an increased number of transmural blood vessels. Microscopic observation shows fossa, crypt abscess, and plasma cell and lymphocyte infiltration. All of which are consistent with the clinical and histological manifestations of CD (Gleason and Patterson, 1982; Bronner, 2004; Franczak et al., 2018). Creeping fat, an extra-intestinal manifestation of CD, is manifested by the migration and wrapping of mesenteric adipose tissue (MAT) to around sites of intestinal inflammation. Creeping fat is visually striking alongside the patchy lesions (Sheehan et al., 1992; Peyrin-Biroulet et al., 2007). Connie et al. showed that translocation of the gut microbiota is the main driving factor leading to the formation of creeping fat (Ha et al., 2020). Interestingly, the remodeling of MAT was also found in Y. enterocolitica-infected mice (Antonopoulos et al., 2008; Han et al., 2017).

In current clinical practice, the diagnosis of CD always needs to determine whether Y. enterocolitica infection exists. While positive cultures obtained from the mesenteric lymph nodes, pharyngeal exudates, peritoneal fluid, or blood can successfully diagnose Y. enterocolitica infection (Centers for Disease, 2011), this laborious and time-consuming method has been gradually replaced by molecular detection, including serological testing, such ELISA (Laporte et al., 2015) and agglutination (Paerregaard et al., 1991; Sonnevend et al., 2005) detection of the presence of specific antibodies (such as IgG, IgG, IgA, and IgM) against YOPs (such as LorV (V antigen), YopD, and Yop M) produced by B cells with the help of intestinal dendritic cells. Triantafillidis et al. recommended that all patients with terminal-ileitis as evidenced by endoscopic and histological images should be tested for YOP-specific antibodies to determine whether the terminal-ileal CD is associated with Y. enterocolitica infection (Triantafillidis et al., 2020). However, serological testing also has many concomitant difficulties, including cross-reactions with other intestinal microbes (Golkocheva-Markova et al., 2008). Currently, more sensitive, highly accurate and precise methods, such as PCR and multiplex PCR, have been used to clinically and preclinically detect the transposon and virulence genes of pathogens within mucosal tissues (Zakharchuk, 1965; Ye et al., 2014; Engberg et al., 2021). High-throughput sequencing technologies, such as metagenomic sequencing (Kim et al., 2021), will help to increase our understanding of the diversity and function of the gut microbiota and promote the development of new molecular diagnostic tools, thereby achieving accurate diagnosis and treatment of diseases.

Y. enterocolitica infection should be considered in the treatment of CD. Although Y. enterocolitica infection is self-limiting in most cases, there is a risk of systemic infection if patients receive immunosuppressive therapy due to presumptive CD. Timely antibiotic treatment is necessary for some patients with Y. enterocolitica infection complications. A study by George et al (Arnold et al., 2002). showed that ciprofloxacin, a first-line anti-Y. enterocolitica antibiotic may be an effective agent when added to the treatment of moderately active, resistant CD. We speculated that this result might be related to the clearance effect of ciprofloxacin on Y. enterocolitica. In addition, the presence of the high-pathogenicity island (HPI) in highly virulent strains (e.g., type 1B/O:8), which is responsible for the siderophore yersiniabactin-mediated iron uptake, facilitates the absorption and utilization of iron by Y. enterocolitica and promotes its growth under iron-limiting conditions (Bancerz-Kisiel et al., 2018). Thus, although iron-deficiency anemia is a common extraintestinal complication of CD (Stein et al., 2010; Azghari et al., 2016), Y. enterocolitica infection should be excluded prior to administering iron supplementation to anemic CD patients, as increased iron levels may increase the risk for sepsis (Cross et al., 2015). In addition, Y. enterocolitica should be considered in the treatment of CD, for it may alter drug activity through metabolism, thereby enhancing or inhibiting the clinical effect of the treatment.

Eliminating Y. enterocolitica may improve the symptoms of CD patients. For example, exclusive enteral nutrition (EEN) is used as an effective first-line treatment for inducing remission in pediatric Crohn’s disease (Ruemmele et al., 2014; Levine et al., 2019). It consists only of liquid nutrition that eliminates suspected food causative agents such as allergenic proteins, refined sugar, and pathogenic microorganisms including the Y. enterocolitica. In addition, there is evidence that EEN modulates the activity and structure of intestinal microbiota and consequently attenuates inflammation (Lionetti et al., 2005). The treatment of CD with probiotics has also gained substantial research interest (Guslandi et al., 2000; Sokol et al., 2008), as they exhibit high safety. Probiotics also have inhibitory effects on the presence of Y. enterocolitica infection through several mechanisms: 1) production of inhibitory substances, 2) blockade of intestinal surface adhesion sites, 3) nutrient competition, and 4) stimulation of mucosal and systemic immunity. For example, Bujalance et al. found that 20 strains of lactic acid bacteria had inhibitory effects on Y. enterocolitica and this inhibition was mainly attributed to the decrease in pH caused by glucose fermentation by lactic acid bacteria (Bujalance et al., 2014). Lactobacillus fermentum attenuates the proinflammatory effect of Y. enterocolitica on human epithelial cells (Frick et al., 2007). Both in vivo and in vitro experiments have shown that the probiotic Escherichia coli strain Nissle 1917 inhibits the invasion of Y. enterocolitica by secreting antibacterial compounds (Altenhoefer et al., 2004). Within the patient‐based studies, administration of Saccharomyces boulardii has been reported helpful in maintaining remission and bowel sealing (Garcia Vilela et al., 2008). However, we do note that, in some studies, probiotics did not perform better than placebo in inducing the remission of CD (Limketkai et al., 2020). More researches are needed to determine what strains and at what dose probiotics become more useful as part of a clinical intervention.

As described above, some strategies targeting Y. enterocolitica may have unexpected potential diagnostic and therapeutic applications in the treatment of CD. Development of agents with specific toxicity for Y. enterocolitica or its virulent strains is promising and merits more investment. In addition, based on the immunosuppressive effect of some Yops, these proteins may become innovative biological agents for the treatment of CD by inhibiting the release of chemokines and inflammatory factors and affecting the migration of neutrophils (Grabowski et al., 2017), thereby alleviating CD inflammation. The establishment of engineered bacteria or vaccines of Y. enterocolitica for reliable targeted drug delivery and intestinal immune regulation may provide unexpected potential treatments for abnormal submucosal immune responses in CD.

In the past decades, there has been a substantial increase in the understanding of microbiota-host interactions. Specifically, there has been considerable advancements regarding the molecular mechanisms of Y. enterocolitica in host immune disorders. However, the role of Y. enterocolitica in CD pathogenesis remains unclear for several reasons.

First, some studies have declared that they failed to find differences in the Y. enterocolitica infection rates between CD patients and controls (Hugot et al., 2021). One reason for this different conclusion may be the detection method. Some clinical analyses (16S rRNA and metagenomic sequencing) of the gut microbiota in CD patients have primarily focused on stool samples (Khan et al., 2021). Using only stool to assess the gut microbiota can potentially dilute the signal of low-abundance bacteria, such as Y. enterocolitica, which are typically diluted by the high abundance of “transient bacteria”. Therefore, more appropriate clinical samples, such as mucosal lesions, Peyer’s patches, mesenteric lymph nodes, and creeping fat should be detected. Another factor that hinders understanding the close association between Y. enterocolitica and CD is the complex and diverse clinical manifestations of Y. enterocolitica infection. The clinical pathogenicity of different serotypes of Y. enterocolitica is different, and similarities of Y. enterocolitica infection with CD may only manifest with highly virulent strains. Thus, focusing on the role of pathogenic Y. enterocolitica in CD is essential to furthering this area of research. Additionally, other pathogens are also involved in the pathology of CD, such as adherent-invasive Escherichia coli, as reviewed by Rolhion et al (Rolhion and Darfeuille-Michaud, 2007). and Palmel et al (Palmela et al., 2018).

Second, the function and mechanism of Y. enterocolitica in the pathogenesis of CD are still uncertain. It has been reported that some Y. enterocolitica-positive patients were subsequently diagnosed with CD (Lamps et al., 2001; Zippi et al., 2006). However, evidence of an association between Y. enterocolitica and CD does not directly indicate a causal relationship between the two, nor does it rule out the possibility that Y. enterocolitica is only a confounding factor in the etiology of CD. In addition, CD patients are often immunodeficient, and as such, receive immunosuppressive treatment, which leads to an increased risk of infection with pathogenic bacteria, such as Y. enterocolitica. However, whether secondary infection of Y. enterocolitica affects the incidence rate, severity, and recurrence rate of CD is also worthy of further study.

Specifically, a multicenter, prospective study with large sample size, as well as additional studies using relevant genetically susceptible and gnotobiotic mice, coculture of gut-microbiota, immune cells and intestinal organoid on a chip, advanced sequencing technologies such as single-cell transcriptome and spatial transcriptome are needed to elucidate the development and progression of Y. enterocolitica in CD. Understanding the molecular mechanisms of the pathogenesis of these two diseases provides prospects for better diagnosis and treatment. More rapid and sensitive tools for the detection of Y. enterocolitica and strict food monitoring and management are conducive to reducing the chance of pathogenic Y. enterocolitica infection. They will help control gastrointestinal infections and even possibly CD. Innovative biological agents based on Y. enterocolitica, such as YOPs, genetically engineered bacteria, and vaccines, may also have unexpected potential therapeutic applications in the treatment of CD. In addition, considering the infection of Y. enterocolitica in CD patients and taking more proper management is very important. In summary, studying the relationship between Y. enterocolitica and CD may provide a basis for clarifying the etiology and pathogenesis of CD, formulating a reasonable and practical treatment plan, and determining the prognosis of the disease.

YB and Z-SL conceived the original idea. XF, LK, and Y-FQ collected and wrote the manuscript with contributions from all other authors. All authors contributed to the article and approved the submitted version.